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ABSTRACT
Co-stimulation is an integral part of T cell signaling involved in almost all facets 
of T cell biology. While much is known about co-stimulation in differentiation and 
function of conventional αβ T cells, less is known about how co-stimulation affects 
the development and programming of γδ T cells. In this study, we have investigated 
the role of inducible T cell co-stimulator (ICOS) on the development of γδ T cells. We 
show that ICOS is expressed by a population of immature Vγ2+CD45RBlow γδ T cells 
predisposed to interleukin-17 (IL-17) production. We found that treatment with ICOS 
specific antibodies drastically reduces fetal development of IL-17-producing γδ T cells 
by agonistic actions, and that ICOS deficient mice have a significant increase in the 
population of IL-17-producing Vγ2+ γδ T cells in the thymus, spleen, lymph nodes and 
skin and exhibit exacerbated sensitization responses to 2,4-dinitrofluorobenzene. In 
conclusion, this study demonstrates that development of IL-17-producing Vγ2+ γδ T 
cells is reduced by ICOS signaling in the thymus.
INTRODUCTION
T cells are a critical part of the adaptive immune 
system and can be divided into two distinct lineages based 
on their expression of either the αβ or the γδ T cell receptor 
(TCR). αβ T cells recognize peptide antigens presented 
on classical MHC molecules. Antigen recognition leads 
to clonal expansion of the antigen-specific αβ T cells and 
mounting of a highly specific albeit delayed adaptive 
immune response. In contrast, γδ T cells can recognize 
more diverse antigens and mount a rapid response without 
the need for clonal expansion, thereby providing an 
important link between the innate and adaptive immune 
systems [1].
T cell development occurs in the thymus and can be 
followed by the differential expression of the co-receptors 
CD4 and CD8. The earliest T cell progenitors are CD4/
CD8 double negative (DN). The lineage choice between 
the αβ and γδ T cell lineages has already occurred by the 
late DN stage, where cells that have committed to the αβ 
lineage will continue to become CD4/CD8 double positive 
(DP), express the αβ TCR on the surface and eventually 
become either CD4 or CD8 single positive (SP). Unlike 
αβ T cells, development of γδ T cells remains poorly 
defined. Cells that are to become γδ T cells stay DN 
and start expressing the γδ TCR. The earliest γδ T cells 
are believed to be CD25+CD24+ [2]. Upon maturation 
γδ T cells down-regulate CD25 and up-regulate CD73 
[3]. Later in their maturation, γδ T cells down-regulate 
CD24 to become fully mature CD24-CD73+ γδ T cells. 
Distinct γδ T cell subsets develop in waves and can be 
characterized by their expression of different Vγ segments 
in their TCR. Starting from around day 13 of gestation, 
the earliest γδ T cells appear in the thymus and express 
the Vγ3 chain (Vγ3+; Garman nomenclature [4]). These 
are followed by a wave of Vγ4+ γδ T cells. The last γδ T 
cells to develop are the Vγ1.1+ and Vγ2+ subsets, which 
are the two primary subsets in the adult thymus. Unlike 
conventional αβ T cells, γδ T cells are pre-programmed 
for their effector function during their development in the 
thymus [5, 6]. The major γδ effector T cells are IFNγ or IL-
17 producers. They can be distinguished by their surface 
expression of CD27 and CD45RB with IFNγ producers 
being CD27+CD45RB+ and IL-17 producers being CD27-
CD45RB- [2, 6]. A recent study show that IL-17-producing 
γδ T cells develop primarily during the fetal and neonatal 
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stages of life, while IFNγ-producing γδ T cells develop 
throughout all stages of life [7]. The different Vγ subsets 
are enriched within certain effector populations with 
Vγ1.1+ and Vγ3+ γδ T cells being primarily IFNγ producers 
and Vγ2+ and Vγ4+ γδ T cells being primarily IL-17 
producers. The mechanisms behind the differential pre-
programming of γδ T cells are still largely unknown. Some 
studies suggest that the pre-programming is determined by 
either the presence or absence of a selecting ligand within 
the thymus [5, 6], while others point toward cytokines and 
other local environmental factors as playing a role [8-12]. 
Inducible T cell co-stimulator (ICOS) is an inducible 
surface receptor of the CD28 co-receptor family. Unlike 
CD28 and CTLA4, ICOS does not bind CD80/CD86 
but instead has a single distinct ligand called the ICOS 
ligand (ICOS-L). ICOS shows similar signaling properties 
as CD28, and constitutive expression of ICOS has been 
found to rescue CD28 deficiency [13]. Although CD28 
and ICOS both activate the PI3K/AKT signaling axis [14, 
15], ICOS has been reported to induce PI3K-independent 
calcium flux, indicating that other auxiliary pathways 
may be induced by ICOS signaling compared to CD28 
signaling [16]. Studies of ICOS knockout (ICOS-/-) mice 
and sanroque mice have shown that while the overall 
T cell populations are largely unaffected by lack or 
constitutive expression of ICOS [17], ICOS is important 
for the development and effector function of specific T cell 
subsets [18]. The most prominent phenotype of ICOS-/-  
mice is their loss of follicular helper T (Tfh) cells that are 
needed for germinal center formation and B cell antibody 
isotype switching [19-21]. Additionally, ICOS-/- mice 
show reduced Th1- and Th2 responses manifesting in an 
inability to control viral and worm infections. Likewise, 
the development of Th1- and Th2-mediated autoimmune 
diseases is reduced in ICOS-/- mice [22-24]. ICOS has 
also been found to be critical for Th17 differentiation and 
function in both mice and humans [25]. 
While T cells have been reported to develop 
normally in the thymus of ICOS-/- mice [17], ICOS 
together with CD28 have been shown to be important for 
the development of both thymic natural killer T (NKT) 
cells and the recently discovered natural Th17 (nTh17) 
cells [26, 27]. Furthermore, ICOS:ICOS-L interactions 
have been implicated in the development of human thymic 
natural Treg cells [28]. ICOS is expressed by γδ T cells 
[29] already in the thymus, but little is known regarding 
its function on these cells. Until now, no studies have 
investigated the effect of ICOS signaling in the thymic 
development and effector programming of γδ T cells. In 
this study, we characterize ICOS expression on developing 
T cells in the thymus. We identify expression of ICOS 
on a subpopulation of immature γδ T cells enriched for 
markers associated with IL-17 production. Treatment 
with ICOS specific antibodies drastically and selectively 
reduced the development of IL-17-producing γδ T cells 
in the fetal thymus. Finally, we show that ICOS-/- mice 
show altered subset distributions within their γδ T cell 
population with a 40-50% increase in IL-17-producing 
Vγ2+ γδ T cells in multiple immune organs and the skin 
and exhibit an increased skin response to the contact 
allergen 2,4-dinitrofluorobenzene (DNFB).
RESULTS
ICOS is expressed by mature CD4 or CD8 SP 
thymocytes
ICOS is nominally an inducible co-receptor but 
is also expressed at steady-state by several immune cell 
populations. To examine how ICOS is expressed during T 
cell development, we isolated thymocytes from C57BL/6 
mice and analyzed expression of ICOS by flow cytometry. 
We found that ICOS is expressed by several populations 
of thymocytes in adult mice (Figure 1A). Almost all CD4 
SP and more than 50% of the CD8 SP T cells express high 
levels of ICOS, whereas CD4/CD8 DP cells do not (Figure 
1A). 
During conventional αβ T cell development, 
progenitors start expressing the TCR at the CD4/CD8 DP 
stage at which point TCR selection occurs. After selection 
the remaining cells continue maturation and down-
regulate CD24 before being exported from the thymus. 
To determine the relative timing of ICOS expression in 
developing T cells, we further characterized the expression 
of TCRβ and CD24 within the CD4/CD8 populations 
(Figure 1B). Within the DP, CD8 and CD4 SP populations 
ICOS is mainly expressed on TCRβ+ cells whereas the 
TCRβ- cells are mainly ICOS-. Furthermore, the majority 
of ICOS+TCRβ+ cells had started to downregulate CD24 
and showed high to intermediate expression of CD24. 
The CD8+CD24highTCRβ- population most probably 
represented transitory immature SP cells (ISP) and they 
did not express ICOS. Taken together, these observations 
suggested that ICOS is expressed immediately after 
surface expression of the αβ TCR. Such an expression 
pattern is in good concordance with ICOS expression 
being induced by TCR signaling [30]. The CD4/CD8 
DN cells contained a small population of cells expressing 
ICOS (Figure 1A). To determine which cell types within 
the DN fraction are expressing ICOS, we next analyzed 
the expression of TCRβ and TCRδ within the ICOS+ 
and ICOS- DN cells (Figure 1C). The ICOS+ DN cells 
are highly enriched for cells expressing either the αβ or 
γδ TCR as compared with the ICOS- cells (Figure 1C). 
This indicates that in the DN fraction, ICOS is primarily 
expressed on mature TCR-expressing cells similar to what 
we observed for the CD4 and CD8 SP populations (Figure 
1B).
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ICOS is expressed by a large subset of immature 
γδ T cells enriched for Vγ2+CD45RBlow cells
Developing γδ T cells up-regulate the TCR-
inducible molecule CD73 during their early development 
and can be divided into three maturation stages by their 
expression of CD24 and CD73 with immature cells being 
CD24highCD73-, committed cells being CD24highCD73+ 
and mature cells being CD24-CD73+ cells [3]. If γδ T 
cells showed a similar expression pattern of ICOS as 
conventional αβ T cells, we would expect ICOS to be 
expressed on CD24highCD73+ cells as these cells are 
likely to have undergone recent TCR-mediated selection. 
Surprisingly, we found that ICOS was expressed by γδ T 
cells across all maturation stages including the immature 
CD24highCD73- stage (Figure 2A). The expression of ICOS 
within the CD73- population was surprising as both ICOS 
and CD73 are believed to be induced by TCR signaling. 
Therefore, we wanted to determine if ICOS expression on 
these immature cells marked a particular subpopulation 
of γδ T cells. In adult mice, γδ T cells can be divided into 
two major subsets by their expression of the Vγ1.1 or Vγ2 
TCR chain. While CD27 has been shown to distinguish 
IFNγ (CD27+) and IL-17 (CD27-) producing γδ T cells [2], 
we found that all immature CD24highCD73- cells express 
CD27, thus rendering CD27 a poor marker to distinguish 
IFNγ and IL-17-producing γδ T cells at this stage (data 
not shown). However, a recent study has associated low 
expression of CD45RB with IL-17 production in γδ T cells 
[6]. We found that immature CD24highCD73- γδ T cells 
that express ICOS are enriched for Vγ2+ cells and almost 
exclusively express low levels of CD45RB (Figure 2B). 
We found a similar enrichment for Vγ2+CD45RBlow cells 
in the ICOS+ fraction of γδ T cells in the lymph nodes 
(Figure 2C). Finally, it is worth noting that the ICOS+ 
fraction does not contain many of the very early CD25+ γδ 
T cells, indicating that ICOS is up-regulated on immature 
γδ T cells after expression of the γδ TCR (Figure 2B).
Figure 1: ICOS is expressed by mature CD4 or CD8 SP thymocytes. Representative flow cytometric plots of thymocytes 
isolated from 7-8 weeks old mice and stained for CD4, CD8, CD24, ICOS, TCRβ and TCRδ. A. Expression of ICOS within the major 
thymic populations defined by CD4 and CD8. B. Expression of CD24 and TCRβ within the different ICOS- (left) and ICOS+ (right) 
subpopulations. C. Expression of TCRβ and TCRδ within the ICOS- (left) and ICOS+ (right) CD4/CD8 DN subpopulation. Numbers denote 
mean percentage ± standard error of mean (SEM) of the gated populations, (n = 12).
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Together, this showed that ICOS is expressed 
on a variety of different thymocyte populations in both 
the αβ and γδ T cell lineages. Unlike αβ T cells, which 
express ICOS during early post-selection stages, γδ T 
cells show ICOS expression across all maturity stages 
with a bias towards a subset of cells with IL-17-producing 
characteristics.
Treatment with ICOS specific antibodies severely 
reduces the development of IL-17-producing γδ T 
cells
The previous results indicated that ICOS might 
play a role in the development of IL-17-producing γδ T 
cells. Murine γδ T cells programmed to produce IL-17A 
develop mainly during fetal and neonatal life [7] and 
may be distinguished by their high expression of CD44 
and lack of CD27 [2]. To investigate the role of ICOS 
interactions during the development and programming of 
γδ T cells, we made fetal thymic organ cultures (FTOC) 
with randomized thymic lobes from embryonic day 15 
(e15) fetuses and treated them with antibodies added to 
the culture medium. Two different anti-ICOS antibodies 
were used, namely 7E.17G9 reported to be blocking [30-
32] and C398.4A reported to be stimulating [33] as well 
as an isotype control. After 7 days in culture, the lobes and 
culture medium were harvested and T cell development 
was analyzed using flow cytometry (Figure 3A). Treatment 
with ICOS specific antibodies did not seem to affect the 
development of conventional αβ T cells as DP and CD4/
CD8 SP populations appeared largely normal across the 
different treatments (data not shown). In contrast, within 
the TCRδ+ populations we found a highly significant and 
specific depletion of CD27-CD44+ cells in the cultures 
treated with 7E.17G9 both within the lobes and the 
Figure 2: ICOS is expressed by a large subset of immature γδ T cells enriched for Vγ2+CD45RB- cells. Representative 
flow cytometric plots of CD4/CD8 depleted thymocytes or inguinal lymph nodes lymphocytes isolated from 7-8 weeks old mice and stained 
for ICOS, TCRδ, TCRβ, TCR Vγ2, TCR Vγ1.1, CD24, CD25, CD45RB and CD73. A. Expression of the maturation markers CD24 and 
CD73 on ICOS- (left) and ICOS+ (right) cells within CD4/CD8 DN γδ T cells. B. Expression of TCR Vγ1.1, TCR Vγ2, CD25 and CD45RB 
within ICOS- (left) and ICOS+ (right) immature CD24+CD73- γδ T cells, (n = 8). C. Expression of TCR Vγ2 and CD45RB within ICOS- 
(left) and ICOS+ (right) γδ T cells from inguinal lymph nodes, (n = 6). Numbers denote mean percentage ± SEM of the gated populations.
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culture medium (Figure 3A-3C). Although not statistically 
significant, cultures treated with C398.4A likewise showed 
a reduction in the CD27-CD44+ population (Figure 3A-
3C). While the depletion of the CD27-CD44+ was highly 
significant, complete depletion was not obtained with 
neither antibody. As some γδ T cells are present before 
e15, we speculated that some cells evaded the anti-ICOS 
antibody treatment at a time point critical for the depletion. 
To determine if the incomplete depletion was due to 
the timing of the cultures, we conducted new 7E.17G9 
antibody-treated FTOC experiments with randomized 
thymic lobes from embryonic day 14 (e14) fetuses. Similar 
to the e15 cultures, we observed a significant reduction 
in the CD27-CD44+ population in the e14 cultures treated 
with the 7E.17G9 antibody as compared with the isotype 
control (Figure 3D, 3E). We also stimulated thymocytes 
from the e14 cultured lobes with PMA and ionomycin 
for 4 hours and analyzed them for the expression of 
intracellular IL-17A and IFNγ. In concordance with the 
reduced CD27-CD44+ population, we found a significant 
decrease in the fraction of γδ T cells producing IL-17A 
in cultures treated with the 7E.17G9 anti-ICOS antibody 
(Figure 3F, 3G).
Taken together, these experiments show that 
treatment of FTOC with the ICOS specific antibodies 
selectively reduces development of IL-17-producing γδ T 
cells.
Genetic ICOS deficiency causes subtle variations 
in fetal γδ T cell effector pre-programming
The significant depletion of IL-17-producing γδ 
T cells in FTOC treated with the supposedly blocking 
7E.17G9 anti-ICOS antibody encouraged us to determine 
if ICOS is required for the normal development of this 
subset of γδ T cells. To investigate this, we setup timed 
mating with pairs of mice genetically deficient for ICOS 
(ICOS-/-) or control mice (ICOS+/+). Similar to previous 
experiments, the fetuses were removed at embryonic day 
Figure 3: Treatment with ICOS specific antibodies severely reduces the development of IL-17-producing γδ T cells. 
FTOC treated with anti-ICOS antibodies and cultured for 7 or 11 days. A. Representative flow cytometric plots showing CD27 and CD44 
expression within γδ T cells harvested from the lobes (top) or culture medium (bottom) of e15 + 7 days FTOC. B.-E. Quantification of 
the CD44+CD27- population percentages within γδ T cells harvested from thymic lobes (B, D) or culture medium (C, E) from e15 + 7 
days FTOC (B, C) or e14 + 11 days FTOC (D, E) (n = 4). F. Representative flow cytometric plots showing intracellular IL-17A and IFNγ 
expression in γδ T cells from e14 + 11 days FTOC thymic lobes stimulated for 4 hours with PMA and ionomycin. G. Quantification of the 
IL-17A+ fraction of e14 + 11 days FTOC γδ T cells stimulated for 4 hours with PMA and ionomycin (n = 3). Each sample was pooled from 
a well containing 4-5 individual lobes. Bars denote mean percentage ± SEM of the gated populations.
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15 (e15) and lobes were cultured in FTOC for 7 days 
followed by analysis using flow cytometry. Overall we 
saw very little difference between the ICOS-/- and ICOS+/+ 
fetal thymic lobes. αβ T cell development (data not shown) 
as well as γδ T cell proportions, Vγ1.1, Vγ2 and Vγ3 
subset distributions and surprisingly CD27-CD44+ and 
CD27+CD44+ populations were all unchanged (Figure 
4A-4C). We did see a reduction of Vγ2+ cells within the 
otherwise unchanged CD27+CD44+ population (Figure 4D, 
4E). This could indicate that while genetic ICOS deficiency 
does not reduce the development of fetal IL-17-producing 
γδ T cells (Figure 4F, 4G), it may subtly change Vγ2+ γδ T 
cell effector programming. The normal proportion of IL-17- 
producing γδ T cells (CD27-CD44+) in the ICOS-/- fetal 
thymic lobes was in stark contrast to the phenotype seen 
in FTOC cultures treated with the 7E.17G9 anti-ICOS 
antibody. This made us speculate whether the 7E.17G9 
antibody does in fact block ICOS signaling or if it shows 
ICOS-independent effects or agonistic properties. To test 
for ICOS-independent effects, we repeated similar FTOC 
experiments with ICOS-/- fetal thymic lobes and treated 
the lobes with the 7E.17G9 anti-ICOS antibody or the 
isotype control. In these experiments we saw no effect 
of the 7E.17G9 antibody on the CD27-CD44+ population 
(data not shown), indicating that the observed antibody 
effect in ICOS+/+ FTOC is indeed ICOS dependent. In 
order to investigate if the 7E.17G9 antibody does in 
fact block ICOS signaling, we needed a larger number 
of ICOS expressing cells than we could get from γδ 
T cell populations. We therefore stimulated splenic T 
cells overnight with immobilized anti-CD3 antibodies. 
This induced ICOS expression on almost all the T cells 
(data not shown). These cells were then pre-incubated 
with high concentrations of the 7E.17G9 antibody for 5 
minutes followed by addition of the stimulating C398.4A 
anti-ICOS antibody. Cells were harvested just prior to the 
addition of the C398.4A antibody (t = 0), after 5 (t = 5) and 
15 minutes (t = 15), and ICOS stimulation was assessed by 
AKT phosphorylation using western blotting (Figure 4H). 
We found that both 7E.17G9 and C398.4A increased AKT 
phosphorylation as compared with untreated controls. 
Interestingly, pre-incubation with the supposedly blocking 
7E.17G9 antibody did not reduce but rather increased 
AKT phosphorylation after subsequent addition of the 
stimulating C398.5A antibody at both the 5 and 15 minute 
time points.
Figure 4: Genetic ICOS deficiency causes subtle variations in fetal γδ T cell effector pre-programming. A.-G. FTOC 
of lobes harvested at embryonic day 15 from timed pregnant ICOS+/+ or ICOS-/- mice and cultured for 7 days. A-C) Representative flow 
cytometric plots (A) and quantifications (B, C) showing expression of CD27 and CD44 within the γδ T cell population of cultured lobes. 
D-G) Expression of TCR Vγ1.1 and TCR Vγ2 within CD27+CD44+ (D, E) and CD27-CD44+ (F, G) γδ T cell populations. Thymic lobes 
were analyzed individually (n = 32). Bars denote mean percentage ± SEM of the gated populations. H. Western blot analysis of AKT 
phosphorylation in anti-CD3 propagated splenic T cells treated with anti-ICOS antibodies for 0, 5 and 15 minutes. Bars represent mean ± 
SEM of relative AKT phosphorylation (pY-AKT/total-AKT intensity) normalized to the 5 minute sample without anti-ICOS antibodies (n 
= 3).
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Together, these observations indicated that the 
7E.17G9 antibody exhibits ICOS dependent signaling 
properties and that it is not strictly a blocking antibody in 
our culture conditions. Consequently, these results indicate 
that the negative effect on the development of IL-17-
producing γδ T cells induced by ICOS antibody treatment 
is mediated by agonistic ICOS signaling. Such negative 
regulation would not be present in ICOS-/- thymic lobes 
and is further supported by the normal development of this 
subset in ICOS-/- fetal thymic lobes.
Figure 5: ICOS-/- mice have an increased population of IL-17-producing Vγ2+ γδ T cells. Comparison of γδ T cell populations 
from ICOS+/+ and ICOS-/- mice. A. Representative flow cytometric plots showing CD27 and CD44 expression within γδ T cells from iLN. 
B. Quantification of the CD27-CD44+ fraction of γδ T cells from the indicated organs. C. Representative flow cytometric plots showing TCR 
Vγ1.1 and TCR Vγ2 expression within CD27-CD44+ γδ T cells from iLN. D. Quantification of the TCR Vγ2+ fraction of the CD27-CD44+ γδ 
T cell population from the indicated organs. E. Representative flow cytometric plots showing IL-17A and IFNγ expression in γδ T cells from 
iLN stimulated with PMA and ionomycin. F. Quantification of the IL-17A+ fraction of the γδ T cell population from the indicated organs 
stimulated with PMA and ionomycin. G. Representative flow cytometric plots showing TCR Vγ1.1 and TCR Vγ2 expression in IL-17A+ 
γδ T cells from iLN. H. Quantification of the TCR Vγ2+ fraction of IL-17A+ γδ T cells from the indicated organs. Bars denote mean 
percentage ± SEM of the gated populations (n = 8).
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ICOS-/- mice have an increased population of IL-17-
producing Vγ2+ γδ T cells
To determine how endogenous ICOS signaling 
affects the development of IL-17-producing γδ T cells as 
well as other lymphocyte populations, we performed a 
thorough T cell phenotyping of the thymus and secondary 
lymphoid organs in adult ICOS-/- mice and compared with 
age-matched ICOS+/+ controls. Overall we found only few 
differences in the distribution of the major lymphocyte 
subsets between ICOS-/- and ICOS+/+ mice (Supplementary 
Figure S1A-G) aside from the previously reported 
decrease in memory CD4+ T cells and a skewing of the 
B to T cell distribution in the lymph nodes [34, 35]. The 
inguinal lymph nodes (iLN) seemed to be most affected 
by the lack of ICOS (Supplementary Figure S1A). We 
found a selective and significant 40-50% increase in the 
CD27-CD44+ γδ T cell population in the iLN of ICOS-/- 
mice (Figure 5A, 5B). This population also showed a 
significant enrichment of Vγ2+ cells, likely accounting 
for the overall increase in the population (Figure 5C, 5D). 
Interestingly, we found an even more drastic enrichment of 
Vγ2+ cells within the CD27-CD44+ γδ T cells of the other 
investigated immune organs (Figure 5D). The increase in 
Vγ2+ cells was not limited to immune organs as we also 
found a drastic increase in this population within the skin 
of ICOS-/- mice (Supplementary Figure S1H, I). To verify 
that the increase in the CD27-CD44+ γδ T cell population 
in ICOS-/- mice actually corresponded to an increase in 
IL-17-producing γδ T cells, we stimulated cells from the 
lymphoid organs with PMA and ionomycin and analyzed 
for intracellular cytokines by flow cytometry. We found a 
significant 40-50% increase in IL-17A+ γδ T cells in the 
iLN of ICOS-/- mice similar to the increase in the CD27-
CD44+ population (Figure 5E, 5F). It is worth noting 
that the IFNγ+ population is unchanged, showing that 
the increase in IL-17A+ γδ T cells is specific and not due 
to an overall increase in γδ T cell cytokine production 
(Figure 5E and Supplementary Figure S1E). Interestingly, 
the increase in IL-17A+ cells was specific to the γδ T cell 
lineage as the overall IL-17A+ lymphocyte population in 
the iLN and other organs seemed to be slightly albeit not 
significantly decreased (Supplementary Figure S1F, G). 
Similar to the CD27-CD44+ population we also found a 
significant enrichment of Vγ2+ cells within the IL-17A+ 
population indicating that the additional Vγ2+ cells are 
capable of IL-17 production (Figure 5G, 5H).
Together, these results showed that ICOS deficiency 
results in a significantly increased population of Vγ2+ γδ 
T cells in all investigated organs and that this enrichment 
increases the total size of the IL-17-producing γδ T cell 
population in the iLN. 
ICOS-/- mice exhibit exacerbated responses during 
sensitization with DNFB
Contact allergy is a T cell-mediated inflammatory 
disease manifesting as redness, swelling and itching 
of the skin following exposure to allergens. Both γδ 
T cells and IL-17 are required in the development of 
contact allergy [36, 37]. To investigate whether the 
increased numbers of IL-17-producing γδ T cells impact 
immune responses in ICOS-/- mice, we sensitized ICOS-
/- and ICOS+/+ mice by painting the dorsal side of their 
ears with DNFB or vehicle control (olive oil in acetone; 
OOA) for three consecutive days. We measured the 
resulting acute ear swelling response 5 days after the 
first painting. DNFB treatment induced drastic ear 
swelling as compared with OOA treatment (Figure 
6A). Importantly, ICOS-/- mice showed significantly 
stronger ear swelling than their ICOS+/+ counterparts 
(Figure 6A). In parallel, we observed increased numbers 
of lymphocytes in the draining lymph nodes of ICOS-
/- compared to ICOS+/+ mice (Figure 6B). To determine 
if the exacerbated sensitization response in ICOS-/- was 
accompanied by increased IL-17A-producing Vγ2+ γδ 
T cells, we analyzed the draining lymph nodes cells by 
flow cytometry. We found a significant increase in both 
the number and fraction of CD27-CD44+ and IL-17A+Vγ2+ 
γδ T cells in ICOS-/- mice compared to ICOS+/+ mice 
(Figure 6C-6F). Taken together, these observations support 
that the increased numbers of IL-17A-producing γδ T cells 
in ICOS-/- mice play a physiologically relevant role during 
immune responses.
DISCUSSION
In this study, we have characterized ICOS 
expression in developing T cells in the thymus. We found 
ICOS expression on αβ T cells that have recently received 
signals through their TCR. However, we also found 
expression of ICOS on a subpopulation of immature γδ 
T cells thought not to have received TCR signals. This 
population was highly enriched for Vγ2+ cells expressing 
low levels of CD45RB, both of which are associated with 
IL-17A-producing γδ T cells in the periphery. By anti-
ICOS antibody treatment we were able to drastically and 
selectively reduce the development of IL-17-producing γδ 
T cells in the fetal thymus. As similar cultures with ICOS-/- 
thymic lobes did not show an equivalent reduction, we 
could conclude that the impaired development of IL-17-
producing γδ T cells caused by the anti-ICOS antibodies 
in ICOS+/+ mice was directly mediated by ICOS signaling. 
Supporting the notion that ICOS signaling may oppose 
IL-17-producing γδ T cell development, we found a 
specific enrichment of IL-17-producing Vγ2+ γδ T cells 
in multiple immune organs and the skin of ICOS-/- mice. 
These observations indicated that while ICOS expression 
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is dispensable for IL-17-producing γδ T cell development, 
ICOS plays a role in modulating the programming of these 
cells, particularly the ones utilizing the Vγ2 segment. 
While anti-ICOS antibody-mediated reduction of these 
cells was clearly caused during development, we could 
not determine whether the increase in IL-17-producing 
γδ T cells in ICOS-/- mice is due to increased thymic 
development or homeostatic changes in the periphery. 
However, the facts that ICOS is expressed at a very early 
stage in Vγ2+ γδ T cells from ICOS+/+ mice and that the 
specific enrichment of IL-17-producing Vγ2+ γδ T cells is 
present already in the thymus of ICOS-/- mice suggest that 
changes in thymic development and programming account 
for at least a part of the phenotype.
It is intriguing that the 7E.17G9 antibody, reported 
to be blocking [30-32], exerted agonistic ICOS signaling 
in our experiments (Figure 4H). Agonistic signaling 
induced by 7E.17G9 was further supported by the 
apparent discrepancy between antibody treated FTOC and 
the comparable ICOS-/- FTOC experiments (Figure 3 and 
Figure 6: ICOS-/- mice exhibit exacerbated responses during sensitization with DNFB. Comparison of sensitization 
response to DNFB in ICOS+/+ and ICOS-/- mice. A. Ear swelling measurements at day 5 after three consecutive days (day 0-2) treatments 
with DNFB or OOA (vehicle control). B. Quantification of lymphocyte numbers in the draining lymph nodes (dLN) of treated mice at day 
5. C. Representative flow cytometric plots from DNFB treated mice showing CD27 and CD44 expression within TCR Vγ2+ γδ T cells 
from the dLN. D. Quantification of the number of TCR Vγ2+CD27-CD44+ γδ T cells. E. Representative flow cytometric plots from DNFB 
treated mice showing IL-17A and TCR Vγ2 expression in γδ T cells from dLN stimulated with PMA and ionomycin. F. Quantification of 
the number of TCR Vγ2+IL-17A+ γδ T cells in dLN after re-stimulation with PMA and ionomycin. Bars and numbers denote mean ± SEM 
from two independent experiments (n = 6).
Oncotarget19350www.impactjournals.com/oncotarget
Figure 4A-4G). Furthermore, adult ICOS-/- mice show an 
increase in the IL-17-producing γδ T cell population in 
stark contrast to the drastic depletion seen in 7E.17G9 
antibody treated thymic lobes (Figure 3 and Figure 5). 
While the C398.4A antibody induced high levels of AKT 
phosphorylation, its effect on γδ T cell development was 
more modest. This suggests that these antibody clones 
induce different signals downstream of ICOS. This is 
supported by the existence of auxiliary ICOS signaling 
pathways and that the investigated clones have been found 
to bind distinct epitopes [16, 30, 38].
Effector pre-programming of γδ T cells as well as 
commitment to the γδ lineage have been closely tied to 
the TCR signals received by the γδ T cells during their 
development [39-42]. It has previously been reported 
that CD73 is expressed after TCR-ligand interaction, 
and that CD73 marks γδ T cells that have committed to 
the γδ T cell lineage [3]. This makes the appearance of 
ICOS, another TCR-inducible molecule, on CD73- γδ 
T cells puzzling. IL-17-producing γδ T cells have been 
proposed to be programmed by the lack of or weak TCR-
ligand interactions [5, 6], whereas strong TCR-ligand 
interactions induce programming of IFNγ-producing 
γδ T cells or IFNγ- and IL-4-producing γδ NKT cells. 
This could explain a possible mechanism by which co-
stimulatory ICOS signaling drives the integrated signal 
strength above the upper limit for IL-17 imprinting, 
thereby programming IL-17-producing γδ T cell 
progenitors away from their normal fate (Figure 7). In 
addition to the rapid innate-like producers of IL-17 or 
IFNγ described above, recent evidence accumulates for 
the existence of an adaptive-like subset of γδ T cells [43-
45]. Similar to the results of other studies identifying 
factors required for development of IL-17-producing 
γδ T cells [8, 9, 11, 12], we do not observe a reciprocal 
change in IFNγ-producing γδ T cells (Figure 3F, Figure 
5E-5F and Supplementary Figure S1E). This suggests that 
IL-17 and IFNγ-producing γδ T cells are not necessarily 
in direct competition, so that reduction of one subset 
leads to the increase in the other. We suggest that, while 
ICOS signaling drives a supra-threshold response for 
IL-17-producing γδ T cell differentiation, the γδTCR of 
the CD73-ICOS+ cells are unlikely to encounter high-
affinity ligand as this would already have driven the cells 
away from the IL-17-producing fate. Thus, they do not 
receive sufficiently strong signals required for IFNγ pre-
programming and may instead be driven toward a different 
fate, possibly the recently identified adaptive-like subset.
While the role of ICOS has been thoroughly 
investigated in αβ T cells, this is one of the first studies 
showing a role of ICOS in γδ T cells. A recent study 
has shown promising indications for utilizing the 
ICOS-ICOS-L pathway in the context of anti-CTLA-4 
immunotherapy for cancer treatment [46]. Our study 
highlights the need for a deeper knowledge of the different 
cell types affected by the ICOS-ICOS-L pathway to 
determine the utilities and pitfalls such treatments would 
include. This concern is further highlighted by ICOS-/- 
Figure 7: Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus. 
ICOS is expressed by a subpopulation of immature Vγ2+ thymocytes which are biased to develop toward an IL-17 producing phenotype. 
Signaling through ICOS increases the integrated signal strength above the threshold for IL-17 pre-programming, thus diverting developing 
γδ thymocytes away from this fate. 
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mice showing exacerbated skin response to DNFB, despite 
having reduced co-stimulatory capacity and reduced Th17 
development. While ICOS has been shown to be important 
for the differentiation of human Th17 cells, it remains to 
be determined if human IL-17-producing γδ T cells are 
similarly or oppositely regulated by ICOS as in mice, and 
how this affects potential therapies.
MATERIALS AND METHODS
Mice
ICOS−/− mice (B6129P2-Icostm1Mak/J) were purchased 
from The Jackson Laboratory. For FTOC, timed pregnant 
C57BL/6 were obtained from Taconic (Ry, Denmark) or 
bred together with ICOS-/- mice in specific pathogen-free 
facilities at the Department of Experimental Medicine, 
Faculty of Health and Medical Sciences, University 
of Copenhagen, in accordance with national animal-
protection guidelines (license no. 2012-15-2934-00663).
Flow cytometry and cytokine staining
Antibodies against CD4 (RM4-5), CD8 (53-6.7), 
CD19 (1D3), CD24 (M1/69), CD25 (PC61), CD27 
(LG.3A10), CD44 (IM7), CD45RB (C363-16A), CD62L 
(MEL-14), CD73 (TY/11.8), -ICOS (C398.4A), TCRδ 
(GL-3), TCRβ (H57-597), TCRVγ1.1 (2.11), TCRVγ2 
(UC3-10A6), TCRVγ3 (536) and NK1.1 (PK136) were 
purchased from BD Biosciences (Franklin Lakes, NJ, 
USA), BioLegend (San Diego, CA, USA) or eBiosciences 
(San Diego, CA, USA). Fixable Viability Dye (eFluor780 
or eFluor506; eBiosciences, San Diego, CA, USA) or 
7-AAD (BioLegend, San Diego, CA, USA) was used to 
exclude dead cells in the analysis.
Thymus, spleen and lymph nodes were harvested 
from 7-8 week old C57BL/6 or ICOS-/- mice. For 
enrichment of thymic γδ T cells, thymocytes were 
depleted with anti-CD4 and anti-CD8 magnetic beads 
(Miltenyi Biotec). For all stainings, antibodies were 
diluted in Brilliant Stain Buffer (BD Biosciences, San 
Diego, CA, USA) and stained for 30-40 minutes in the 
dark on ice. For intracellular cytokine staining, single-cell 
suspensions were stimulated with PMA (25 ng/ml) and 
ionomycin (625 ng/ml) in complete medium including 
monensin (2.08 µg/ml) for 4 hours at 37°C. Cells were 
stained for surface markers, fixed and permeabilized using 
BD Cytofix/Cytoperm (BD Biosciences). Permeabilized 
cells were stained with anti-IL-17 (TC11-18H10) or anti-
IFNγ (XMG1.2). All samples were analyzed on a BD 
LSRFortessa at the Core Facility for Flow Cytometry, 
Faculty of Health and Medical Sciences, University 
of Copenhagen. Data was analyzed using the FlowJo 
software (Treestar, Ashland, OR, USA).
Fetal thymus organ culture and anti-ICOS 
treatment
Fetuses were harvested from timed-pregnant 
C57BL/6 or ICOS-/- mice at day 14 or 15 of gestation 
(measured as days after female was plugged), after which 
thymic lobes were cultured on isopore membrane filters 
(Merck Millipore Ltd.) placed in the surface tension of 
2 mL DMEM (20% heat-inactivated fetal bovine serum, 
10 mM HEPES, 0.05 mM β-mercaptoethanol, 4 mM 
L-glutamine, 100 IU/mL penicillin and streptomycin) in 
12 well plates (ThermoScientific). 4-8 lobes were cultured 
on each membrane filter. Half-way through cultures, the 
medium was carefully removed and replaced. After 7 or 
11 days for e15 and e14 cultures, respectively, the lobes 
and culture medium was harvested and minced through a 
70µm cell-strainer followed by flow cytometric analysis 
as described above.
For anti-ICOS treated FTOC, LEAF-purified anti-
ICOS (7E.17G9 and C398.4A) or anti-Rat IgG2b isotype 
was purchased from BioLegend (San Diego, CA, USA) 
and added to the culture medium to a final concentration 
of 5 µg/mL.
Anti-ICOS stimulation and quantification of 
AKT-phosphorylation by western blotting
Spleens were harvested from 7-8 week old C57BL/6 
mice and minced through a 70 µm cell strainer. After 
washing, the cells were resuspended in 0.165 M NH4Cl 
and left undisturbed for 11 minutes on ice to lyse red 
blood cells. Splenocytes were enriched for T cells by 
depletion of B cells using magnetic anti-mouse IgG 
beads (ThermoFisher; cat. no. 11031). To induce ICOS 
expression, cells were cultured in flat-bottom 96 well 
plates (ThermoScientific) pre-coated with 5 µg/mL 
anti-CD3 (145-2C11) overnight. Cells were harvested 
and 5x106 cells were aliquoted into tubes according 
to treatment and starved for 30 minutes in 100 µl PBS 
(containing 10 mM HEPES) at 37ºC. Cells were pre-
incubated 5 minutes with anti-ICOS (7E.17G9) prior 
to addition of anti-CD3 (145-2C11) and anti-ICOS 
(C398.4A) all to a final concentration of 50 µg/mL and 
kept in water bath at 37ºC throughout. At 0, 5 and 15 
minutes after addition of antibodies, 30µl was harvested 
from each treatment and added to 900 µl ice cold PBS and 
put on ice. Samples were lysed and analyzed by western 
blotting as previously described [47] using anti-Phospho-
AKT (Thr308) Rabbit mAb and anti-AKT (Cell Signaling 
Technology)
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Skin sensitization to DNFB
Mice were painted with 25 µl 0.15% 
2,4-dinitrofluorobenzene (DNFB; Sigma-Aldrich) in 1:4 
olive oil:acetone (OOA) mixture on the dorsal side of both 
ears for three consecutive days (days 0-2). On day 5, mice 
were euthanized and ear thickness was measured on both 
ears using an engineer’s micrometer (Mitutoyo, Tokyo, 
Japan). Ear draining (d)LN were excised and analyzed by 
flow cytometry as described above.
Statistical analysis
Statistical analyses were performed using Student’s 
t test with a 5% significance level, un-paired observations 










MHC Major histocompatibility complex
OOA Olive oil in acetone (1:4)
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